IT1229484B - Virus ricombinante delle malattie esantematiche dei vertebrati. - Google Patents

Virus ricombinante delle malattie esantematiche dei vertebrati.

Info

Publication number
IT1229484B
IT1229484B IT8821772A IT2177288A IT1229484B IT 1229484 B IT1229484 B IT 1229484B IT 8821772 A IT8821772 A IT 8821772A IT 2177288 A IT2177288 A IT 2177288A IT 1229484 B IT1229484 B IT 1229484B
Authority
IT
Italy
Prior art keywords
exanthematic
vertebrates
diseases
recombinant virus
recombinant
Prior art date
Application number
IT8821772A
Other languages
English (en)
Other versions
IT8821772A0 (it
Inventor
Enzo Paoletti
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27492413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT1229484(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of IT8821772A0 publication Critical patent/IT8821772A0/it
Application granted granted Critical
Publication of IT1229484B publication Critical patent/IT1229484B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IT8821772A 1987-08-28 1988-08-29 Virus ricombinante delle malattie esantematiche dei vertebrati. IT1229484B (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9071187A 1987-08-28 1987-08-28
US11033587A 1987-10-20 1987-10-20
US18605488A 1988-04-25 1988-04-25
US23439088A 1988-08-23 1988-08-23

Publications (2)

Publication Number Publication Date
IT8821772A0 IT8821772A0 (it) 1988-08-29
IT1229484B true IT1229484B (it) 1991-09-03

Family

ID=27492413

Family Applications (1)

Application Number Title Priority Date Filing Date
IT8821772A IT1229484B (it) 1987-08-28 1988-08-29 Virus ricombinante delle malattie esantematiche dei vertebrati.

Country Status (17)

Country Link
JP (3) JP3348156B2 (it)
KR (1) KR970011149B1 (it)
AR (1) AR241939A1 (it)
AT (1) AT408549B (it)
AU (2) AU2427588A (it)
BE (1) BE1002134A5 (it)
CH (2) CH679934A5 (it)
DE (4) DE10399031I1 (it)
DK (1) DK175904B1 (it)
FR (1) FR2621487B1 (it)
GB (1) GB2217718B (it)
IL (1) IL87581A0 (it)
IT (1) IT1229484B (it)
LU (2) LU90951I2 (it)
NL (4) NL195051C (it)
NZ (1) NZ225970A (it)
WO (1) WO1989003429A1 (it)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
DE10399031I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
US5286639A (en) * 1987-09-16 1994-02-15 Nippon Zeon Co., Ltd. Recombinant avipoxvirus
DE3813093A1 (de) * 1988-04-19 1989-11-09 Immuno Ag Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
WO1989012684A1 (en) * 1988-06-24 1989-12-28 National Research Development Corporation Fowlpox virus non-essential regions
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
CA2001001A1 (en) * 1988-10-21 1990-04-21 Matthew M. Binns Fowlpox virus promoter
US6248333B1 (en) 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5204243A (en) * 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) * 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
IE71643B1 (en) * 1990-11-20 1997-02-26 Virogenetics Corp A recombinant poxviral vaccine for canine distemper
US5759841A (en) * 1990-11-20 1998-06-02 Virogenetics Corporation Immunological composition of measles virus utilizing recombinant poxvirus
US5756102A (en) * 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5503834A (en) * 1990-11-20 1996-04-02 Virogenetics Corporation Measles virus recombinant poxvirus vaccine
US5338679A (en) * 1991-01-08 1994-08-16 Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US5766597A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
WO1992015672A1 (en) * 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
US5766598A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
US5756101A (en) * 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
CA2106464A1 (en) * 1991-03-20 1992-09-21 Enzo Paoletti Malaria recombinant poxvirus vaccine
EP0592546B1 (en) * 1991-06-14 2003-05-28 Virogenetics Corporation Immunodeficiency virus recombinant poxvirus vaccine
EP0597016A4 (en) * 1991-07-26 1996-04-24 Virogenetics Corp Infectious bursal disease virus recombinant poxvirus vaccine.
EP1380651A2 (en) * 1991-08-26 2004-01-14 Baxter Healthcare S.A. Recombinant fowlpox virus with intact FPV-tk-gene
US5443831A (en) * 1991-10-29 1995-08-22 University Of Delaware Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus
PT623172E (pt) * 1992-01-13 2005-02-28 Virogenetics Corp Vacina de virus vaccinia recombinante do virus da doenca de marek
US5869312A (en) * 1992-01-13 1999-02-09 Syntro Corporation Recombinant swinepox virus
US6127163A (en) * 1992-01-13 2000-10-03 Syntro Corporation Recombinant swinepox virus
US6033904A (en) * 1992-01-13 2000-03-07 Syntro Corporation Recombinant swinepox virus
US6251403B1 (en) 1992-01-13 2001-06-26 Syntro Corporation Recombinant swinepox virus
US6328975B1 (en) 1992-01-13 2001-12-11 Syntro Corporation Recombinant swinepox virus
US6497882B1 (en) 1992-01-13 2002-12-24 Syntro Corporation Recombinant swinepox virus
CA2142325A1 (en) * 1992-09-21 1994-03-31 William T. L. Lee Recombinant retroviral vector against felv and/or fiv
AU727278B2 (en) * 1993-02-26 2000-12-07 Syntro Corporation Recombinant fowlpox viruses and uses thereof II
WO1994019015A1 (en) * 1993-02-26 1994-09-01 Syntro Corporation Recombinant fowlpox viruses and uses thereof
US6136318A (en) * 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
US5925358A (en) * 1993-02-26 1999-07-20 Syntro Corporation Recombinant fowlpox viruses and uses thereof
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5843742A (en) * 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
EP0753581A1 (en) 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
US5858373A (en) * 1995-12-01 1999-01-12 Virogenetics Corporation Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
EP2112225A1 (en) 1996-07-25 2009-10-28 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Recombinant pox virus for immunization against tumor-associated antigens
US6106825A (en) * 1997-05-07 2000-08-22 University Of Florida Entomopoxvirus-vertebrate gene delivery vector and method
AU3910097A (en) * 1997-08-05 1999-03-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Live recombinant vaccine comprising inefficiently or non-replicating vir us
US6248582B1 (en) * 1997-10-08 2001-06-19 Imran Khan Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
JPH11165762A (ja) 1997-12-01 1999-06-22 Lintec Corp チップ体搬送用カバーテープおよび封止構造体
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
EP1980617A1 (en) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2374346C (en) 1999-06-28 2010-06-22 Jordan J. N. Tang Inhibitors of memapsin 2 and use thereof
CN1254541C (zh) 2000-02-23 2006-05-03 史密丝克莱恩比彻姆生物有限公司 新化合物
EP1319069B1 (en) 2000-06-28 2008-05-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU2002305914A1 (en) 2001-01-12 2002-10-21 Chiron Corporation Nucleic acid mucosal immunization
DK1370668T3 (da) * 2001-03-08 2006-06-06 Akzo Nobel Nv Leporipox-baserede vektorvacciner
JP4499311B2 (ja) * 2001-04-27 2010-07-07 シャープ株式会社 放送受信端末
CA2446788A1 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030198621A1 (en) 2001-07-05 2003-10-23 Megede Jan Zur Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1581119B1 (en) 2001-12-17 2013-01-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
DK1589934T3 (en) 2003-01-06 2015-12-21 Corixa Corp Certain AMINOAL COOLER GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND APPLICATION
US20070073048A1 (en) 2003-05-15 2007-03-29 Ying Lian Hiv polynucleotides and polypeptides derived from botswana mj4
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
EP2298340B1 (en) 2004-09-22 2014-04-16 GlaxoSmithKline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
AU2006335256B2 (en) 2005-11-22 2012-10-18 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
US20090081157A1 (en) 2006-01-09 2009-03-26 Richard Syd Kornbluth Immunostimulatory Combinations for Vaccine Adjuvants
EP2207035B1 (en) 2006-03-14 2013-10-16 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
WO2008106551A2 (en) 2007-02-28 2008-09-04 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. Brachyury polypeptides and methods for use
US9593340B2 (en) 2007-10-15 2017-03-14 Admedus Vaccines Pty Ltd. Expression system for modulating an immune response
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
CA2748788C (en) 2009-01-05 2021-02-09 Epitogenesis Inc. The use of a composition comprising mustard oil, catechin, and vitamin a for modulating an immune response
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
EP3360566B1 (en) 2009-11-20 2019-12-25 Oregon Health&Science University Methods for detecting a mycobacterium tuberculosis infection
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
EP2670426B1 (en) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
CN103608030A (zh) 2011-06-21 2014-02-26 昂科发克特公司 用于治疗和诊断癌症的组合物和方法
US10561720B2 (en) 2011-06-24 2020-02-18 EpitoGenesis, Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
ES2752190T3 (es) 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
CN105682674A (zh) 2013-04-17 2016-06-15 建新公司 用于治疗和预防黄斑变性的组合物和方法
US9988617B2 (en) 2013-05-21 2018-06-05 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
US10172916B2 (en) 2013-11-15 2019-01-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
BR112016017817A2 (pt) 2014-02-06 2017-10-10 Genzyme Corp composições e métodos para o tratamento e a prevenção de degeneração macular
EP3194446B1 (en) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
JP2018511655A (ja) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
WO2016168601A1 (en) 2015-04-17 2016-10-20 Khalid Shah Agents, systems and methods for treating cancer
WO2016172479A1 (en) 2015-04-22 2016-10-27 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
EP4276106A3 (en) 2015-05-13 2024-01-24 The United States of America as represented by the Secretary of the Department of Health and Human Services Methods and compositions for inducing an immune response using conserved element constructs
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
US10550379B2 (en) 2015-06-29 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
CA3006779A1 (en) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
US11814627B2 (en) 2016-06-20 2023-11-14 The Board Of The Leland Stanford Junior University Circular RNAs and their use in immunomodulation
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
CA3075532A1 (en) 2017-09-15 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University Multiplex production and barcoding of genetically engineered cells
US10917454B1 (en) 2019-08-01 2021-02-09 Rohde & Schwarz Gmbh & Co. Kg System and method for ATC voice quality assurance
WO2023070072A1 (en) 2021-10-21 2023-04-27 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Retroelement-generated transcription factor decoys
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
EP4426832A1 (en) 2021-11-03 2024-09-11 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
US20250215422A1 (en) 2022-03-25 2025-07-03 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads RT-DNA Fidelity and Retron Genome Editing
US20250223586A1 (en) 2022-03-25 2025-07-10 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Methods of assessing engineered retron activity, and uses thereof
WO2023183627A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
CN120344660A (zh) 2022-07-18 2025-07-18 雷纳嘉德医疗管理公司 基因编辑组分、系统和使用方法
WO2024044673A1 (en) 2022-08-24 2024-02-29 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Dual cut retron editors for genomic insertions and deletions
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024233791A1 (en) 2023-05-11 2024-11-14 Seelos Therapeutics, Inc. Methods of treating neurodegenerative disorders
AU2024357861A1 (en) 2023-10-12 2026-04-23 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK489481A (da) * 1980-11-10 1982-05-11 Searle & Co Plasmidvektor og frmgangsmaade til fremstilling deraf
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
JPH0795954B2 (ja) * 1982-11-30 1995-10-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
FR2563434B1 (fr) * 1984-04-25 1986-07-25 Transgene Sa Vaccin contre la rage et procede pour sa preparation
WO1986000528A1 (en) * 1984-07-05 1986-01-30 Genex Corporation Cloned gene and method for making and using the same
DD235669A1 (de) * 1985-03-26 1986-05-14 Akad Wissenschaften Ddr Verfahren zur herstellung eines blv-kodierten huellproteins
DE3650289T2 (de) * 1985-03-29 1995-08-10 British Tech Group Spike-protein des virus der infektiösen bronchitis.
EP0213894A3 (en) * 1985-08-23 1987-10-21 Advanced Genetics Research Institute Defective viral particle vaccines and methods for their use
AU607399B2 (en) * 1985-09-09 1991-03-07 Cetus Corporation Infectious recombinant virus vaccine for feline leukemia
GR862412B (en) * 1985-09-25 1987-01-23 Oncogen Vaccines and immuinoassays for acquired immune deficiency syndrome
AU602875B2 (en) * 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
AU8075787A (en) * 1986-09-22 1988-04-07 Australian National University, The Recombinant poxviruses
WO1988002022A1 (en) * 1986-09-22 1988-03-24 Commonwealth Scientific And Industrial Research Or Recombinant poxviruses
EP0261940A3 (en) * 1986-09-23 1989-07-05 Applied Biotechnology, Inc. Pseudorabies vaccines and dna vectors for recombination with pox viruses
AU605567B2 (en) * 1987-03-11 1991-01-17 Nippon Zeon Co., Ltd. Recombinant avipoxvirus
DE10399031I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
GB8724885D0 (en) * 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
FR2632863B2 (fr) * 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
WO1989012684A1 (en) * 1988-06-24 1989-12-28 National Research Development Corporation Fowlpox virus non-essential regions
AT400955B (de) * 1989-03-08 1996-05-28 Health Research Inc Rekombinantes pockenvirus-wirtsselektionssystem
KR100372934B1 (ko) * 1990-09-25 2003-12-24 캔탑 파마슈티칼스 리서취 리미티드 형질 상보성 세포주에 의해 생성된 바이러스 결손 백신

Also Published As

Publication number Publication date
NL300130I2 (nl) 2005-11-01
LU91039I2 (fr) 2003-11-05
DK203689A (da) 1989-06-27
DE3890874C2 (de) 2003-03-13
AU1628895A (en) 1995-08-17
AU2427588A (en) 1989-05-02
GB2217718A (en) 1989-11-01
IT8821772A0 (it) 1988-08-29
IL87581A0 (en) 1989-01-31
KR970011149B1 (ko) 1997-07-07
NL300130I1 (nl) 2003-09-01
BE1002134A5 (fr) 1990-07-24
CH679934A5 (it) 1992-05-15
AT408549B (de) 2001-12-27
GB2217718B (en) 1992-05-20
DK203689D0 (da) 1989-04-27
FR2621487A1 (fr) 1989-04-14
GB8908921D0 (en) 1989-08-02
DE3890874C5 (de) 2005-10-20
AU690210B2 (en) 1998-04-23
DE10399031I1 (de) 2004-01-29
NL8820679A (nl) 1989-07-03
CH679933A5 (it) 1992-05-15
JP3826055B2 (ja) 2006-09-27
LU90951I2 (fr) 2003-01-15
NL195051C (nl) 2003-07-01
NL300138I2 (nl) 2004-03-01
DK175904B1 (da) 2005-06-06
NZ225970A (en) 1991-01-29
KR890701757A (ko) 1989-12-21
ATA900788A (de) 1995-05-15
AR241939A1 (es) 1993-01-29
JPH02500879A (ja) 1990-03-29
JP2002186494A (ja) 2002-07-02
JP3348156B2 (ja) 2002-11-20
FR2621487B1 (fr) 1991-10-18
NL300138I1 (nl) 2004-02-02
DE10299049I1 (de) 2004-07-01
JP2002348255A (ja) 2002-12-04
NL300139I1 (nl) 2004-02-02
DE10399032I1 (de) 2004-01-29
WO1989003429A1 (en) 1989-04-20

Similar Documents

Publication Publication Date Title
IT8821772A0 (it) Virus ricombinante delle malattie esantematiche dei vertebrati.
DK603888A (da) Rekombinant virus
ATA902590A (de) Rekombinantes pockenvirus
FI884924A7 (fi) Yhdistelmä-DNA-tekniikalla tuotettuja ihmisimmunoglobuliineja
DK31088A (da) Blodkoaguleringsnedsaettende peptidderivater
NO892251L (no) Fremgangsmaate ved fremstilling av kokkoidosevaksine ved rekombinante teknikker.
FI920737A7 (fi) Terapeuttisia peptidejä
NO912732D0 (no) Farmasoeytiske midler med platina.
FI892507L (fi) Terapeutiska peptider.
FR2620459B1 (fr) Virus recombinant de la vaccine
NO884052L (no) Fremgangsmaate for fremstilling av terapeutisk preparat.
DK250088A (da) Ophthalmologisk praeparat
NO902071D0 (no) Fremgangsmaate og mellomprodukter for fremstilling av oksoftalazinyl-eddiksyrer og analoger derav.
NO882856D0 (no) Fremgangsmaate for fremstilling av immunoundertrykkende peptider.
NO893794D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO894949D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme benzopyranylpyrrolinonderivater.
DK0655503T3 (da) Fremgangsmåde til fremstilling af humant serumalbumin
FI882741A7 (fi) Rekombinantti-HTLV-III-proteiineja ja niiden käyttötapoja.
MX9207407A (es) Mejora de la biodisponibilidad de agentes terapeuticos proteoliticamente labiles.
IT8848638A0 (it) Peptidi contenenti silicio, loro preparazione e loro impiego come medicamenti
NO882491D0 (no) Fremgangsmaate for fremstilling av anti-viralt farmasoeytisk preparat.
NO903116L (no) Fremgangsmaate for fremstilling av aspiringranuler.
NO885446L (no) Fremgangsmaate for fremstilling av kinolincarboxylsyrer.
NO893796D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO884304D0 (no) Ekspresjon av p. falciparum circumsporosoittprotein hos gjaer.

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970827